The Iberian legacy into a young genetic xeroderma pigmentosum cluster in central Brazil.


Journal

Mutation research. Genetic toxicology and environmental mutagenesis
ISSN: 1879-3592
Titre abrégé: Mutat Res Genet Toxicol Environ Mutagen
Pays: Netherlands
ID NLM: 101632149

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 28 12 2019
revised: 22 02 2020
accepted: 25 02 2020
entrez: 9 4 2020
pubmed: 9 4 2020
medline: 22 4 2020
Statut: ppublish

Résumé

In central Brazil, in the municipality of Faina (state of Goiás), the small and isolated village of Araras comprises a genetic cluster of xeroderma pigmentosum (XP) patients. The high level of consanguinity and the geographical isolation gave rise to a high frequency of XP patients. Recently, two founder events were identified affecting that community, with two independent mutations at the POLH gene, c.764 + 1 G > A (intron 6) and c.907 C > T; p.Arg303* (exon 8). These deleterious mutations lead to the xeroderma pigmentosum variant syndrome (XP-V). Previous reports identified both mutations in other countries: the intron 6 mutation in six patients (four families) from Northern Spain (Basque Country and Cantabria) and the exon 8 mutation in two patients from different families in Europe, one of them from Kosovo. In order to investigate the ancestry of the XP patients and the age for these mutations at Araras, we generated genotyping information for 22 XP-V patients from Brazil (16), Spain (6) and Kosovo (1). The local genomic ancestry and the shared haplotype segments among the patients showed that the intron 6 mutation at Araras is associated with an Iberian genetic legacy. All patients from Goiás, homozygotes for intron 6 mutation, share with the Spanish patients identical-by-descent (IBD) genomic segments comprising the mutation. The entrance date for the Iberian haplotype at the village was calculated to be approximately 200 years old. This result is in agreement with the historical arrival of Iberian individuals at the Goiás state (BR). Patients from Goiás and the three families from Spain share 1.8 cM (family 14), 1.7 cM (family 15), and a more significant segment of 4.7 cM within family 13. On the other hand, the patients carrying the exon 8 mutation do not share any specific genetic segment, indicating an old genetic distance between them or even no common ancestry.

Identifiants

pubmed: 32265042
pii: S1383-5718(20)30034-6
doi: 10.1016/j.mrgentox.2020.503164
pii:
doi:

Substances chimiques

DNA-Directed DNA Polymerase EC 2.7.7.7
Rad30 protein EC 2.7.7.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

503164

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Competing Interest The authors declare no competing or conflict interests.

Auteurs

L P Castro (LP)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

M Sahbatou (M)

Foundation Jean Dausset - CEPH, Paris, France.

F S G Kehdy (FSG)

Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.

A A Farias (AA)

Human Genome and Stem-Cell Center, Institute of Biosciences, University of São Paulo (USP), Sao Paulo, Brazil; Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo (USP), São Paulo, Brazil.

A A Yurchenko (AA)

Inserm U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.

T A de Souza (TA)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

R C A Rosa (RCA)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

C T Mendes-Junior (CT)

Department of Chemistry, Forensic and Genomics Research Laboratory, Faculty of Philosophy, Sciences and Letters, University of São Paulo, Ribeirão Preto, Brazil.

V Borda (V)

National Laboratory for Scientific Computation (LNCC), Petropolis, Rio de Janeiro, Brazil.

V Munford (V)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

É A Zanardo (ÉA)

Cytogenomics Laboratory, Department of Pathology, School of Medicine, University of São Paulo (FMUSP), São Paulo, Brazil.

S N Chehimi (SN)

Cytogenomics Laboratory, Department of Pathology, School of Medicine, University of São Paulo (FMUSP), São Paulo, Brazil.

L D Kulikowski (LD)

Cytogenomics Laboratory, Department of Pathology, School of Medicine, University of São Paulo (FMUSP), São Paulo, Brazil.

M M Aquino (MM)

Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.

T P Leal (TP)

Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.

E Tarazona-Santos (E)

Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.

S C Chaibub (SC)

General Hospital of Goiania, Goiania, Brazil.

B Gener (B)

Osakidetza Basque Health Service, Cruces University Hospital. Department of Genetics, Bizkaia, Spain; Biocruces Bizkaia Health Research Institute, Bizkaia, Spain.

N Calmels (N)

Laboratory of Medical Genetics, Institute of Medical Genetics of Alsace (IGMA), Strasbourg, France.

V Laugel (V)

Laboratory of Medical Genetics, Institute of Medical Genetics of Alsace (IGMA), Strasbourg, France.

A Sarasin (A)

UMR8200 CNRS, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.

C F M Menck (CFM)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: cfmmenck@usp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH